SCHEDULE 13G/A: BlackRock Discloses 4.5% Stake in Revolution Medicines, Below 5% Threshold
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Revolution Medicines Inc., holding 8,399,214 shares of common stock as of June 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 8,399,214 shares of Revolution Medicines Inc. common stock.
- This represents 4.5% of the class of securities, placing BlackRock's stake below the 5% reporting threshold for annual Schedule 13G filings.
- BlackRock holds sole voting power over 8,100,605 shares and sole dispositive power over 8,399,214 shares.
- The stated 'Date of Event Which Requires Filing of this Statement' is June 30, 2025, which is a future date.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership filing by an institutional investor, BlackRock, Inc., reporting a passive stake below the 5% threshold. It contains no operational or financial performance data for Revolution Medicines Inc., thus the sentiment is neutral.
Positives
- BlackRock, a major institutional investor, maintains a significant stake in Revolution Medicines Inc., indicating continued confidence in the company.
- The holding is for investment purposes in the ordinary course of business, not for control, suggesting a passive, long-term investment approach.
Negatives
- BlackRock's beneficial ownership of Revolution Medicines Inc. common stock is now below the 5% threshold, which means they are no longer obligated to file annual Schedule 13G reports unless their stake increases above 5% again, suggesting a reduction in their overall stake from previous filings.
Risks
- No specific risks related to Revolution Medicines Inc.'s operations or financial health are disclosed in this filing, as it pertains solely to beneficial ownership.
Future Outlook
The filing itself is a statement of beneficial ownership as of a future date (June 30, 2025), indicating BlackRock's expected holding at that time. No other forward-looking statements regarding Revolution Medicines Inc.'s business or financial performance are provided.
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.
Industry Context
This filing is a routine disclosure by a major institutional asset manager, BlackRock, Inc., regarding its passive investment stake in a biotechnology company, Revolution Medicines Inc. It reflects standard portfolio management activities within the financial industry.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | No management changes for Revolution Medicines Inc. are disclosed. The document details authorized signatories for BlackRock, Inc.'s SEC filings. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Policy Update | BlackRock, Inc. executed a new Power of Attorney, revoking a previous one dated April 30, 2023, to authorize specific individuals to execute SEC filings on its behalf. | 01/21/2025 | This is an internal corporate governance update for BlackRock, Inc. to streamline its SEC filing processes, with no direct impact on Revolution Medicines Inc.'s corporate governance. |
Legal Proceedings
- No legal proceedings are mentioned in this filing.
Related Party Transactions
- No related party transactions are disclosed in this filing.
Stakeholder Impact
- Shareholders: Provides transparency on a major institutional investor's stake. The reduction below the 5% threshold might be interpreted by some investors as a decrease in conviction, while others may view it as routine portfolio rebalancing.
- Management: Awareness of a significant, passive institutional holder and their current ownership level.
Next Steps
- BlackRock, Inc. will continue to monitor its beneficial ownership in Revolution Medicines Inc. and file further amendments if its stake crosses reporting thresholds.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of the previously revoked Power of Attorney. |
| 01/21/2025 | Date the new Power of Attorney was executed by BlackRock, Inc. |
| 06/30/2025 | Date of event which requires filing of this statement, indicating the beneficial ownership position. |
| 07/17/2025 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
Revolution Medicines, BlackRock, SEC filing, Schedule 13G, beneficial ownership, common stock, institutional investment, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.